Cargando…

HDAC-inhibition counteracts everolimus resistance in renal cell carcinoma in vitro by diminishing cdk2 and cyclin A

BACKGROUND: Targeted therapies have improved therapeutic options of treating renal cell carcinoma (RCC). However, drug response is temporary due to resistance development. METHODS: Functional and molecular changes in RCC Caki-1 cells, after acquired resistance to the mammalian target of rapamycin (m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Juengel, Eva, Nowaz, Snigdha, Makarevi, Jasmina, Natsheh, Iyad, Werner, Isabella, Nelson, Karen, Reiter, Michael, Tsaur, Igor, Mani, Jens, Harder, Sebastian, Bartsch, Georg, Haferkamp, Axel, Blaheta, Roman A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4073177/ https://www.ncbi.nlm.nih.gov/pubmed/24935000 http://dx.doi.org/10.1186/1476-4598-13-152

Ejemplares similares

Amygdalin Blocks Bladder Cancer Cell Growth In Vitro by Diminishing Cyclin A and cdk2
por: Makarević, Jasmina, et al.
Publicado: (2014)

Molecular analysis of sunitinib resistant renal cell carcinoma cells after sequential treatment with RAD001 (everolimus) or sorafenib
por: Juengel, Eva, et al.
Publicado: (2015)

Resistance after Chronic Application of the HDAC-Inhibitor Valproic Acid Is Associated with Elevated Akt Activation in Renal Cell Carcinoma In Vivo
por: Juengel, Eva, et al.
Publicado: (2013)

Molecular targeting of prostate cancer cells by a triple drug combination down-regulates integrin driven adhesion processes, delays cell cycle progression and interferes with the cdk-cyclin axis
por: Wedel, Steffen, et al.
Publicado: (2011)

HDAC inhibition as a treatment concept to combat temsirolimus-resistant bladder cancer cells
por: Juengel, Eva, et al.
Publicado: (2017)

Mechanisms behind Temsirolimus Resistance Causing Reactivated Growth and Invasive Behavior of Bladder Cancer Cells In Vitro
por: Juengel, Eva, et al.
Publicado: (2019)

HDAC Inhibition Counteracts Metastatic Re-Activation of Prostate Cancer Cells Induced by Chronic mTOR Suppression
por: Makarević, Jasmina, et al.
Publicado: (2018)

Cross-communication between histone H3 and H4 acetylation and Akt-mTOR signalling in prostate cancer cells
por: Makarević, Jasmina, et al.
Publicado: (2014)

Intensified antineoplastic effect by combining an HDAC-inhibitor, an mTOR-inhibitor and low dosed interferon alpha in prostate cancer cells
por: Tsaur, Igor, et al.
Publicado: (2015)

Bladder Cancer Metastasis Induced by Chronic Everolimus Application Can Be Counteracted by Sulforaphane In Vitro
por: Justin, Saira, et al.
Publicado: (2020)

Sulforaphane inhibits proliferation and invasive activity of everolimus-resistant kidney cancer cells in vitro
por: Juengel, Eva, et al.
Publicado: (2016)

Influence of the HDAC Inhibitor Valproic Acid on the Growth and Proliferation of Temsirolimus-Resistant Prostate Cancer Cells In Vitro
por: Makarević, Jasmina, et al.
Publicado: (2019)

Amygdalin Influences Bladder Cancer Cell Adhesion and Invasion In Vitro
por: Makarević, Jasmina, et al.
Publicado: (2014)

Resistance to the mTOR-inhibitor RAD001 elevates integrin α2- and β1-triggered motility, migration and invasion of prostate cancer cells
por: Tsaur, I, et al.
Publicado: (2012)

I Publish in I Edit? - Do Editorial Board Members of Urologic Journals Preferentially Publish Their Own Scientific Work?
por: Mani, Jens, et al.
Publicado: (2013)

Allyl-, Butyl- and Phenylethyl-Isothiocyanate Modulate Akt–mTOR and Cyclin–CDK Signaling in Gemcitabine- and Cisplatin-Resistant Bladder Cancer Cell Lines
por: Rutz, Jochen, et al.
Publicado: (2022)

Combining the receptor tyrosine kinase inhibitor AEE788 and the mammalian target of rapamycin (mTOR) inhibitor RAD001 strongly inhibits adhesion and growth of renal cell carcinoma cells
por: Juengel, Eva, et al.
Publicado: (2009)

Evaluation of TKTL1 as a biomarker in serum of prostate cancer patients
por: Tsaur, Igor, et al.
Publicado: (2016)

Integrin α2 and β1 Cross-Communication with mTOR/AKT and the CDK-Cyclin Axis in Hepatocellular Carcinoma Cells
por: Juratli, Mazen A., et al.
Publicado: (2022)

Publication of Original Research in Urologic Journals – A Neglected Orphan?
por: Mani, Jens, et al.
Publicado: (2012)

Concomitant Use of Sulforaphane Enhances Antitumor Efficacy of Sunitinib in Renal Cell Carcinoma In Vitro
por: Tsaur, Igor, et al.
Publicado: (2022)

sE-cadherin serves as a diagnostic and predictive parameter in prostate cancer patients
por: Tsaur, Igor, et al.
Publicado: (2015)

Chronic Sulforaphane Administration Inhibits Resistance to the mTOR-Inhibitor Everolimus in Bladder Cancer Cells
por: Justin, Saira, et al.
Publicado: (2020)

Mycophenolate mofetil modulates adhesion receptors of the beta1 integrin family on tumor cells: impact on tumor recurrence and malignancy
por: Engl, Tobias, et al.
Publicado: (2005)

The CDK Subunit CKS2 Counteracts CKS1 to Control Cyclin A/CDK2 Activity in Maintaining Replicative Fidelity and Neurodevelopment
por: Frontini, Mattia, et al.
Publicado: (2012)

CCL2 Chemokine as a Potential Biomarker for Prostate Cancer: A Pilot Study
por: Tsaur, Igor, et al.
Publicado: (2015)

Chemoresistance is associated with increased cytoprotective autophagy and diminished apoptosis in bladder cancer cells treated with the BH3 mimetic (−)-Gossypol (AT-101)
por: Mani, Jens, et al.
Publicado: (2015)

Renal cell carcinoma alters endothelial receptor expression responsible for leukocyte adhesion
por: Juengel, Eva, et al.
Publicado: (2016)

Correction: Renal cell carcinoma alters endothelial receptor expression responsible for leukocyte adhesion
por: Juengel, Eva, et al.
Publicado: (2017)

Plant-Derived Sulforaphane Suppresses Growth and Proliferation of Drug-Sensitive and Drug-Resistant Bladder Cancer Cell Lines In Vitro
por: Xie, Hui, et al.
Publicado: (2022)

Olive Mill Wastewater Inhibits Growth and Proliferation of Cisplatin- and Gemcitabine-Resistant Bladder Cancer Cells In Vitro by Down-Regulating the Akt/mTOR-Signaling Pathway
por: Rutz, Jochen, et al.
Publicado: (2022)

Use of complementary and alternative medicine before and after organ removal due to urologic cancer
por: Mani, Jens, et al.
Publicado: (2015)

Cyclin K goes with Cdk12 and Cdk13
por: Kohoutek, Jiri, et al.
Publicado: (2012)

Molecular docking analysis of piperine with CDK2,CDK4,Cyclin D and Cyclin T proteins
por: Rekha, Umapathy Vidhya, et al.
Publicado: (2020)

Mistletoe Extracts from Different Host Trees Disparately Inhibit Bladder Cancer Cell Growth and Proliferation
por: Juengel, Eva, et al.
Publicado: (2023)

Counteraction between Astrin-PP1 and Cyclin-B-CDK1 pathways protects chromosome-microtubule attachments independent of biorientation
por: Song, Xinhong, et al.
Publicado: (2021)

Cdk-counteracting phosphatases unlock mitotic exit
por: Queralt, Ethel, et al.
Publicado: (2008)

Nuclear Import of Cdk/Cyclin Complexes: Identification of Distinct Mechanisms for Import of Cdk2/Cyclin E and Cdc2/Cyclin B1
por: Moore, Jonathan D., et al.
Publicado: (1999)

Sulforaphane Reduces Prostate Cancer Cell Growth and Proliferation In Vitro by Modulating the Cdk-Cyclin Axis and Expression of the CD44 Variants 4, 5, and 7
por: Rutz, Jochen, et al.
Publicado: (2020)

Cell cycle progression mechanisms: slower cyclin-D/CDK4 activation and faster cyclin-E/CDK2
por: Zhang, Wengang, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_q9bne77cbkhrl7mqft1miuad8t